

Drug recommendations from Area Prescribing Committee – 15th June 2017

APC recommendations

	Drug	Recommendation	Cumbria implications
<i>The following RAG ratings have been allocated.</i>	Nil this meeting		

Lothian formulary decisions

Drugs(s)	Formulation	Trade name	Indication	Date considered by Lothian	Decision	Current Cumbria RAG rating	NICE	Commission by	Cumbria APC decision
Vortioxetine	5mg, 10mg, 20mg film coated tablet	Brintellix®	Treatment of major depressive episodes in adults	19 th April 2017	Included on the Additional list, specialist use only, for the indication in question,	GREEN	TA367	CCG	GREEN Remains Green in line with NICE
Pirenzepine	50mg tablets	Gatrozepin®	Treatment of clozapine induced hypersalivation	19 th April 2017	Included on the LJJ as a prescribing note, Specialist use only, RED under the ADTC “policy for the use of unlicensed (and off-label use) medicines in NHS Lothian.				RED
Insulin aspart	100 units/ml solution for injection in vial, cartridge, pre-filled pen	Fiasp®	Treatment of diabetes mellitus in adults	19 th April 2017	Not included in the LJJ pending protocol.				GREY

Botulinum toxin type A		Botox®	Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).	19 th April 2017	Not included in the LJF because clinicians have not responded to an invitation to apply for formulary inclusion	RED	TA260	CCG	Remains RED In line with NICE
Evolocumab		Repatha®	In adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in certain circumstances.	19 th April 2017	Not included in the LJF because clinicians have not responded to an invitation to apply for formulary inclusion	RED	TA394	CCG	Remains RED in line with NICE
Abatacept		Orencia®	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	19 th April 2017	Not Recommended for use in NHS Scotland	RED	TA375	CCG	RED Remains RED in line with NICE
Tenofovir alafenamide		Vemlidy®	Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).	19 th April 2017	Not Recommended for use in NHS Scotland		Terminated appraisal March 17	CCG	GREY Until NICE publish TA

Ticagrelor		Brilique®	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.	19 th April 2017	Not Recommended for use in NHS Scotland	AMBER	TA236	CCG	AMBER Remains Amber in line with NICE
Colecalciferol	Tablets 4000 units	Desunin®	Treatment of Vitamin D deficiency in paediatric patients with cystic fibrosis.	25 th Jan 2017	Included on the LJF as second choice, specialist initiation, for the indication in question.			CCG	AMBER
DEKAs® PLUS	Liquid		Vitamin supplementation for pancreatic insufficient cystic fibrosis in paediatric patients. DEKAs® PLUS will replace AquADEKs® that has been discontinued.	8 th March 2017	Included on the LJF as first choice, general use, GREEN under the ADTC “policy for the use of unlicensed (and off-label use) medicines in NHS Lothian.			CCG	AMBER
ADEK plus			Fat soluble vitamin supplementation in paediatric patients with cystic fibrosis. This will replace vitamin A and D capsules, vitamin BPC capsules and Aquadeks.	25 th Jan 2017	Included on the LJF as first choice, general use, GREEN under the ADTC “policy for the use of unlicensed (and off-label use) medicines in NHS Lothian.			CCG	AMBER

NTAG Treatment Appraisal recommendations

Drug/indication	NTAG recommendation	Cumbria APC decision
Nil this meeting		

NICE Technology assessments

	Drug	Condition	Summary	Commissioner	Cumbria APC Decision
TA440	Pegylated liposomal irinotecan	Treating pancreatic cancer after gemcitabine.	<p>Pegylated liposomal irinotecan, in combination with 5-fluorouracil and leucovorin, is not recommended, within its marketing authorisation, for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.</p> <p>This guidance is not intended to affect the position of patients whose treatment with pegylated liposomal irinotecan was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop</p>		BLACK
TA441	Daclizumab	Treating relapsing – remitting multiple sclerosis.	<p>Daclizumab is recommended as an option for treating multiple sclerosis in adults, only if:</p> <p>The person has active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and</p> <p>Alemtuzumab is contraindicated or otherwise unsuitable and</p> <p>The company provides the drug with the discount agreed in the patient access scheme</p>	NHSE	RED

TA442	Ixekizumab	Treating moderate to severe plaque psoriasis	<p>Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if:</p> <p>The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10</p> <p>The disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them, and</p> <p>The company provides the drug with the discount agreed in the patient access scheme.</p>	CCG	RED
TA443	Obeticholic acid	Treating primary biliary cholangitis	<p>Obeticholic acid is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme.</p> <p>Assess the response to obeticholic acid after 12 months. Only continue if there is evidence of clinical benefit.</p>	NHSE	RED
TA444	Afatinib	Treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy.	TERMINATED APPRAISAL		GREY
TA445	Certolizumab pegol and secukinumab	Treating active psoriatic arthritis after inadequate response to DMARDs	<p>Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:</p> <p>It is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or</p> <p>The person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.</p>	CCG	RED

			<p>Certolizumab pegol is only recommended if the company provides it as agreed in the patient access scheme.</p> <p>Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:</p> <p>It is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or</p> <p>The person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or</p> <p>TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).</p> <p>Secukinumab is only recommended if the company provides it as agreed in the patient access scheme.</p>		
--	--	--	--	--	--

NICE Clinical guidelines

Clinical Guideline	Condition	Date of Publication	Summary of Guidance
NG68	Sexually transmitted infections: condom distribution schemes	April 17	<p>This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.</p> <p>No specific prescribing implications.</p>
NG69	Eating disorders: Recognition and treatment	May 17	<p>This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.</p>